Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .
The Role of Smoking in Abdominal Aortic Aneurysm Development
Abdominal aortic aneurysm is common . The aim of this study was to assess the effect of smoking on prevalence and management .  Patients attending the vascular unit and appropriate controls were prospect ively recruited . A smoking history revealed tobacco exposure in pack years . Serum cotinine was assessed biochemically . Independent risk factors were statistically determined . In all , 202 ( 186 men ) patients were recruited , with 202 ( 197 men ) controls . A total of 69 patients tested positive for cotinine , whereas 39 controls were positive ( P = .001 ) . Smoking and ischemic heart disease were significant predictors for aneurysm prevalence . Cardiac disease emerged as a more important predictor than smoking in symptomatic patients . In noncardiac patients , smoking and hypercholesterolemia were significant risk factors . Smoking is a significant predictor for aneurysm development . In high-risk patients , the cardiac disease process is the most important factor , with control of this imperative . However , in noncardiac patients , smoking cessation and lipid-lowering therapy are crucial
Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .